Very promising depression treatment in the works.
“a $2.8 billion clinical-stage biotech stock, rose by 70.6% over the course of the day in response to new results for its late-stage depression drug”
Like a reverse share split…
We’re missing out!
Nasdaq write up on Axsome’s jump from a $3 share to a $100 share, including its 115% rise in just 5 business days!
Took a dive today (around 7%) after a rival firm has jumped ahead on a rival drug.
Could be a good time to buy?! Exclusivity payout due?